Thanks. I think this is key.
"the FDA said they can only present one group of patients that have one cancer type"
Mgmt changed there language on a lot of things this time, and I think this is the reason they were talking about addition trials for cf33 for the first time really.
I think cf33 is extremely promising, but I do wonder how timeframes have been impacted across the board after this latest roadshow.
GLTA.
Ann: Imugene Corporate Presentation, page-225
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
